Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.86 USD | -4.85% |
|
+2.47% | -36.33% |
03/07 | Oppenheimer Raises Price Target on Pharvaris to $38 From $36, Maintains Outperform Rating | MT |
04/06 | Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.33% | 96Cr | |
+22.15% | 4.66TCr | |
+45.09% | 4.17TCr | |
-2.37% | 4.12TCr | |
+33.84% | 3.24TCr | |
-6.35% | 2.81TCr | |
+20.42% | 2.82TCr | |
+48.83% | 1.45TCr | |
+45.00% | 1.37TCr | |
+0.06% | 1.22TCr |
- Stock Market
- Equities
- PHVS Stock
- News Pharvaris N.V.
- Oppenheimer Raises Price Target on Pharvaris to $38 From $36, Maintains Outperform Rating